Immunochemistry

Research for Bone Metabolism   [Osteoclastic Inhibitors]

Alendronate Sodim Salt Trihydrate
Risedronate Sodium Salt n-Hydrate

Alendronate Na Salt  (Wako Catalog No. 012-22661 (100 mg); 018-22663 (500 mg))
Resedronate Na Salt (Wako Catalog No. 189-02461 (100 mg); 185-02463 (500 mg))

Bone tissue is being remodeled by continuous deossification and ossification. The number of patients with osteoporosis caused by imbalance in the bone metabolism is increasing with the transition to an aging society. This product is a bisphosphonate compound that is selectively distributed in the calcified bone surface to which the osteoclasts are attached. It is released under an acid environment created by the osteoclasts, taken in the cells, and inhibits the bone resorption activity. The inhibition of the bone resorption is considered to be caused by apoptosis induction effect of the osteoclasts and direct suppression of bone resorption of the osteoclasts.

Products

  Alendronate Na Salt Trihydrate

Assay (HPLC): 97.0+ %

Solubility in water: 0.1 g/10 mL

CAS No. : 121268-17-5

  Risedronate Na Salt n-Hydrate

Assay (HPLC): 97.0+ %

Solubility in water: 0.1 g/10 mL

CAS No. : 115436-72-1

Structural Formula

Alendronate Sodium Salt Trihydrate

Alendronate Sodium Salt

Risedronate Sodium Salt n-Hydrate

Risedronate Na Salt

Product List

Osteoclastic Inhibitors

Description
Wako Cat. #  (Package Size)
Alendronate Sodium Salt Trihydrate
012-22661 (100 mg); 018-22663 (500 g)
Risedronate Sodium Salt n-Hydrate
189-02461 (100 mg); 185-02463 (500 g)

Related Product
for enzyme activity staining of tartrate-resistant acid phosphatase and alkaline phosphatase

Description
Wako Cat. #  (Package Size)
TRAP/ALP Stain Kit
294-67001 (60 tests)